Alpha 2.0
Login Register
» Authors » Nungruthai Suntronwong

Nungruthai Suntronwong

Explore the profile of Nungruthai Suntronwong including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 53
Citations 574
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Science
Top 10 Co-Authors
Yong Poovorawan
Nasamon Wanlapakorn
Preeyaporn Vichaiwattana
Sitthichai Kanokudom
Thanunrat Thongmee
Sirapa Klinfueng
Suvichada Assawakosri
Ritthideach Yorsaeng
Natthinee Sudhinaraset
Donchida Srimuan
Published In
Vaccines (Basel)
PLoS One
Sci Rep
Int J Infect Dis
Vaccine
Affiliations
Soon will be listed here.
Recent Articles
1.
Neutralization of omicron subvariants and antigenic cartography following multiple COVID 19 vaccinations and repeated omicron non JN.1 or JN.1 infections
Suntronwong N, Kanokudom S, Duangchinda T, Chantima W, Pakchotanon P, Klinfueng S, et al.
Sci Rep . 2025 Jan; 15(1):1454. PMID: 39789099
The ongoing emergence of SARS-CoV-2 variants, combined with antigen exposures from different waves and vaccinations, poses challenges in updating COVID-19 vaccine antigens. We collected 206 sera from individuals with vaccination-only,...
2.
Significant reduction in Hepatitis B virus infections following 32 years of universal Hepatitis B vaccination as part of EPI, Thailand
Nilyanimit P, Wanlapakorn N, Vichaiwattana P, Wongsrisang L, Klinfueng S, Suntronwong N, et al.
Sci Rep . 2025 Jan; 15(1):1167. PMID: 39774714
This study aimed to evaluate the impact of Thailand's hepatitis B virus (HBV) National Program Immunization (NPI), 32 years post-implementation, on infection rates and immunity in various age groups. A...
3.
Comparison of anti-HCV combined with HCVcAg (Elecsys HCV Duo immunoassay) and anti-HCV rapid test followed by HCV RNA analysis using qRT-PCR to identify active infection for treatment
Kanokudom S, Poovorawan K, Nilyanimit P, Suntronwong N, Aeemjinda R, Honsawek S, et al.
PLoS One . 2024 Nov; 19(11):e0313771. PMID: 39556526
Hepatitis C virus (HCV) infection can cause acute and chronic hepatitis, leading to liver cirrhosis and hepatocellular carcinoma. The World Health Organization aims to eliminate viral hepatitis by 2030 through...
4.
Seroprevalence of antibodies against diphtheria, tetanus, and pertussis across various age groups during the post-COVID-19 pandemic period in Chonburi Province, Thailand
Wanlapakorn N, Suntronwong N, Kanokudom S, Assawakosri S, Vichaiwattana P, Klinfueng S, et al.
Heliyon . 2024 Nov; 10(21):e39889. PMID: 39524738
Background: Limited data exists regarding population immunity against diphtheria, tetanus, and pertussis in Thailand during the post-COVID-19 pandemic period. This study aimed to evaluate the age-specific seroprevalence of anti-diphtheria toxoid...
5.
Viral Etiology Associated With Acute Respiratory Tract Infection Patients in Bangkok, Thailand
Inma P, Suntronwong N, Sinsulpsiri S, Srimaneewiroon S, Poovorawan Y
Cureus . 2024 Sep; 16(8):e66897. PMID: 39280569
Background Acute respiratory infections (ARIs) are a significant public health concern globally. After the relaxation of COVID-19 containment measures, there has been an increase in respiratory tract infections. However, the...
6.
Effectiveness of HPV vaccine as part of national immunization program for preventing HPV infection in Thai schoolgirls after seven years post-vaccination
Nilyanimit P, Vichaiwattana P, Aeemchinda R, Bhunyakitikorn W, Thantithaveewat T, Seetho S, et al.
Hum Vaccin Immunother . 2024 Sep; 20(1):2392330. PMID: 39238340
Thailand introduced a two-dose regimen of bivalent HPV vaccines for Grade 5 schoolgirls, approximately 11 years old, initially piloted in Ayutthaya province in 2014, and nationwide under the National Immunization...
7.
Safety and antibody responses of Omicron BA.4/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study
Kanokudom S, Chansaenroj J, Suntronwong N, Wongsrisang L, Aeemjinda R, Vichaiwattana P, et al.
Vaccine X . 2024 Aug; 20:100538. PMID: 39211731
This cohort study, conducted between July and August 2023, evaluated the adverse events (AEs) and immune response to a bivalent mRNA-1273.222 (containing sequences of the original Wuhan-H1 strain and the...
8.
Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection
Suntronwong N, Kanokudom S, Auphimai C, Thongmee T, Assawakosri S, Vichaiwattana P, et al.
Vaccines (Basel) . 2024 Feb; 12(2). PMID: 38400163
Numerous studies have largely focused on short-term immunogenicity in recovered individuals post mRNA vaccination. However, understanding the long-term durability, particularly in inactivated and adenoviral vectored vaccines, remains limited. We evaluated...
9.
Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3-4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
Assawakosri S, Kanokudom S, Suntronwong N, Chansaenroj J, Auphimai C, Nilyanimit P, et al.
Heliyon . 2024 Jan; 10(1):e23892. PMID: 38226248
Background: Several countries have authorized a booster vaccine campaign to combat the spread of COVID-19. Data on persistence of booster vaccine-induced immunity against new Omicron subvariants are still limited. Therefore,...
10.
Durability of immune response against omicron BA.2 and BA.4/5 and T cell responses after boosting with mRNA and adenoviral vector-based vaccines following heterologous CoronaVac/ChAdOx-1nCov-19 vaccination
Suntronwong N, Kanokudom S, Thatsanathorn T, Thongmee T, Sudhinaraset N, Wanlapakorn N, et al.
Hum Vaccin Immunother . 2023 Nov; 19(3):2283916. PMID: 38014687
Heterologous vaccination with inactivated vaccine followed by adenoviral vector-based vaccine has shown superiority in enhancing immune response compared to homologous primary series. However, data comparing immunity decline after a third...